## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.0% below STRENGTH zone (3.0-6.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.13)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Ninety One SA PTY Ltd Takes $1.49 Million Position in Abbott Laboratories $ABT**
- Source: MarketBeat | 20260101T140811 | Bullish | Relevance: 100%
- Ninety One SA PTY Ltd reported a new position in Abbott Laboratories, purchasing 11,237 shares valued at approximately $1.49 million during Q3. Other institutional investors also adjusted their stakes in the company, which reported Q3 EPS in line with estimates and raised its quarterly dividend. The stock currently holds a "Moderate Buy" consensus rating from analysts with a target price of $147.00.

**2. Merit Financial Group LLC Acquires 20,035 Shares of Abbott Laboratories $ABT**
- Source: MarketBeat | 20260101T114703 | Bullish | Relevance: 100%
- Merit Financial Group LLC significantly increased its stake in Abbott Laboratories by purchasing an additional 20,035 shares, bringing its total holdings to 81,264 shares valued at $10.88 million. This comes as Abbott raised its quarterly dividend to $0.63, offering a 2.0% yield, and analysts maintain a "Moderate Buy" rating with an average target price of $147. The company reported strong Q3 earnings and provided optimistic FY2025 guidance.

**3. The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature**
- Source: FinancialContent | 20260101T101200 | Bullish | Relevance: 100%
- Abbott Laboratories (ABT) has strategically diversified its business, shifting from a focus on COVID-19 testing to metabolic health and consumer-facing biowearables, solidifying its position as a "defensive growth" stock. The company's modern business model is structured around medical devices, diagnostics, nutrition, and established pharmaceuticals, enabling it to capture value across the entire patient journey. Despite ongoing litigation, Abbott's strong financial performance, leadership in innovative products like FreeStyle Libre and Lingo, and robust balance sheet position it for continued growth and stability in the evolving healthcare landscape.

**4. The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature**
- Source: FinancialContent | 20260101T101200 | Bullish | Relevance: 100%
- Abbott Laboratories (ABT) has evolved into a resilient healthcare giant, strategically shifting its focus from COVID-19 testing to metabolic health and consumer-facing biowearables. The company's diversified business model, strong financial performance, and innovative products like FreeStyle Libre and Lingo position it for continued growth despite risks like ongoing litigation. Abbott stands as a defensive growth stock, combining stability with 21st-century innovation.

**5. Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings?**
- Source: Finviz | 20251231T230400 | Somewhat-Bullish | Relevance: 100%
- Abbott Laboratories (ABT) shares have declined by 7.9% over the past six months, prompting investor reevaluation. The company benefits from economies of scale and robust free cash flow margins, averaging 16.8% over five years. However, its long-term revenue growth has been a mediocre 6.4% compounded annually over the same period.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +2.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 21.9x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $216.1B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 21.9 |
| Current P/E | 24.0 |
| YoY Growth | 9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.2% to 0.0% (+2.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.0pp (needs >3.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 44. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.01% (CS: 36) | Neutral |
| RSI_14 | 44.4 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 0.995x | Below |
| vs SMA50 | 0.985x | Below |
| vs SMA200 | 0.955x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $124.19
- **Stop Loss:** $120.13 (3.3% risk)
- **Target:** $128.25 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 354
- **Position Value:** $43,963.26
- **Portfolio %:** 43.96%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*